Sunday 18 October 2026 Export BNTC’s income statement to Excel — free account

Benitec Biopharma Limited

In the quarter to June 2026, EPS fell 11.3%, free cash flow grew 38.9% and total debt fell 46.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

8.11 0.35 −4.14%

Follow BNTC

Alert me

Market cap: $295.1M
P/E: 0.0×
Fwd P/E: −1.8×
Dividend yield: —
F-score: 3/9
Altman Z: −66.02
Beneish M: 11.02
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 22.44

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	2	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 26.99%

Capital & Financial Ratios $m

Market Cap 295.08

Revenue 0.08

Net Income (45.55)

Free Cash Flow (16.62)

Net Debt (179.82)

Current Ratio 34.00

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.79)

P/S ratio 5,034.47

P/B ratio 2.13

Past 5Y EPS Growth —

This Y EPS Growth (22.89%)

Next Y EPS Growth (19.02%)

Next Y revenue growth 101.33%

Next 5Y EPS Growth (12.09%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 73.77%

10-year low 10-year high

P/B against its own 10 years 69.07%

10-year low 10-year high

EV/Sales against its own 10 years 49.40%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	0.77	0.77

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	2	51	98	180
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	1	1	1	2
	4	52	99	182

	2023	2024	2025	2026
Payables	3	4	1	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	4	5	2	5

Compound Annual Growth %

	10y	5y	3y
Sales	(32.19%)	(54.02%)	(9.74%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	29.14%	54.65%	856.94%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’23	—	0	0	0	0
’22	—	0	0	0	0
’21	0	0	0	0	0
’20	0	0	0	—	0
’19	—	—	—	—	12
’18	1	—	—	—	4

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(3)	(4)	(4)	(5)	(17)
’25	(5)	(8)	(3)	(8)	(24)
’24	(5)	(5)	(6)	(3)	(19)
’23	(4)	(6)	(4)	(4)	(18)
’22	(4)	(3)	(3)	(5)	(16)
’21	(2)	(3)	(2)	(5)	(13)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(3)	(4)	(4)	(5)	(17)
’25	(5)	(8)	(3)	(8)	(24)
’24	(5)	(5)	(6)	(3)	(20)
’23	—	—	(4)	(4)	(18)
’23	(4)	(6)	—	—	(18)
’22	—	—	(3)	(5)	(16)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(0.22)	(0.26)	(0.24)	(0.26)	(0.98)
’25	(0.18)	(0.26)	(0.38)	(0.23)	(1.05)
’24	(2.76)	(2.64)	(0.23)	4.45	(1.18)
’23	(7.99)	(3.40)	(2.72)	(0.13)	(14.12)
’22	(2.10k)	(10.03)	(6.80)	(10.54)	(37.92)
’21	(41.67)	(12.86)	(13.95)	(5.10)	(54.93)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	354.45	257.55	105.32	42.84	39.10	2.23	1.86	2.69	9.70	8.06	Analyst estimates 2027–2029 Powerpack
	High	1,397.40	1,249.50	612.00	296.06	178.33	51.85	9.01	13.29	17.15	14.33
People
People	Employees	18	15	21	14	14	18	18	16	19	24
	Revenue/emp, $m	0.46	0.24	0.58	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	8	4	12	0	0	0	0	—	—	—
	Gross margin, %	52.34	(17.80)	96.43	281.37	(108.47)	87.67	100.00	0.00	—	—
	EBT	(4)	(9)	3	(8)	(14)	(18)	(20)	(22)	(38)	(46)
	EBT margin, %	(51.29)	(247.29)	21.39	(8,111.76)	(23,528.81)	(24,942.47)	(26,082.67)	0.00	0.00	0.00
	Net income	0	(9)	3	(8)	(14)	(18)	(20)	(22)	(38)	(46)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	243.11	88.36	242.04	340.00	0.23	0.15	0.05	0.00	0.00	0.00
	Earnings	(124.99)	(219.38)	58.67	(27,591.04)	(54.93)	(37.92)	(14.12)	(1.18)	(1.05)	(0.98)
	Cash flow	(181.99)	(183.86)	95.04	(25,116.67)	(50.82)	(33.07)	(13.00)	(1.06)	(0.65)	(0.35)
	Capex	(3.75)	(1.52)	(7.94)	(313.33)	(0.88)	(0.03)	0.00	(0.01)	0.00	0.00
	Free cash flow	(185.74)	(185.38)	87.10	(25,430.00)	(51.69)	(33.10)	(13.00)	(1.07)	(0.65)	(0.36)
	Book value	471.32	351.87	329.25	34,126.67	79.25	6.00	0.15	2.57	2.69	3.80
	Shares, m	0	0	0	0	0	0	1	18	36	47
Valuation, ×
Valuation, ×	P/E	23.13	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	P/S	0.00	0.00	0.00	0.40	309.21	126.39	75.03	—	—	—
	P/B	0.90	1.22	0.44	0.00	0.91	3.29	27.86	—	—	—
	EV/Sales	0.00	0.00	0.00	(93.60)	(25.20)	79.50	45.62	—	—	—
	EV/FCF	(0.18)	(0.64)	0.50	1.25	0.11	(0.37)	(0.19)	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(6)	(8)	5	(8)	(13)	(16)	(18)	(19)	(24)	(17)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(6)	(8)	4	(8)	(13)	(16)	(18)	(20)	(24)	(17)
Balance, $m
Balance, $m	Working capital	16	14	16	10	19	2	0	47	97	176
	Total debt	—	—	—	0	0	1	0	—	0	0
	Net debt	(13)	(12)	(16)	(10)	(20)	(4)	(2)	(51)	(97)	(180)
	Shareholders’ equity	16	15	17	10	20	3	0	47	97	177
Returns, %
Returns, %	ROA	(27.17)	(53.67)	14.58	(53.69)	(84.22)	(133.14)	(374.86)	(78.94)	(49.96)	(32.28)
	ROIC	(81.96)	(271.58)	184.29	(796.25)	(3,759.96)	0.00	0.00	0.00	0.00	0.00
	ROE	(28.66)	(58.70)	16.76	(61.67)	(91.79)	(159.08)	(1,268.61)	(94.29)	(52.46)	(33.21)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2023 · latest quarter Jun 2023 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARCT Arcturus Therapeutics Holdings Inc.	$320.3M	— (loss-making)	— (loss-making)	−89.54% (below 0%: shrinking)	n/m	−245.65% (below 0%: shrinking)	100.00%	(863.30%)	Compare
AGEN Agenus Inc.	$301.7M	2.3×	4.1×	+34.36% (above 0%: growing)	n/m	−55.25% (below 0%: shrinking)	100.00%	32.72%	Compare
CTNM Contineum Therapeutics, Inc.	$297.2M	— (loss-making)	—	—	n/m	+26.73% (above 0%: growing)	100.00%	0.00%	Compare
ARTV Artiva Biotherapeutics, Inc.	$296.3M	— (loss-making)	— (loss-making)	—	n/m	+13.60% (above 0%: growing)	100.00%	0.00%	Compare
BNTC Benitec Biopharma Limited	$295.1M	— (loss-making)	— (loss-making)	−85.42% (below 0%: shrinking)	n/m	+38.90% (above 0%: growing)	0.00%	0.00%
SRZN Surrozen, Inc.	$294.7M	— (loss-making)	— (loss-making)	+408.65% (above 0%: growing)	n/m	−21.25% (below 0%: shrinking)	100.00%	(207.40%)	Compare
FULC Fulcrum Therapeutics, Inc.	$280.0M	— (loss-making)	— (loss-making)	+27,018.64% (above 0%: growing)	n/m	−13.05% (below 0%: shrinking)	100.00%	0.00%	Compare
OCGN Ocugen, Inc.	$275.9M	— (loss-making)	— (loss-making)	+8.38% (above 0%: growing)	n/m	−13.42% (below 0%: shrinking)	100.00%	(1,105.11%)	Compare
NAUT Nautilus Biotechnology, Inc.	$274.9M	— (loss-making)	—	—	n/m	−3.16% (below 0%: shrinking)	92.11%	(8,296.32%)	Compare
Median of peers	$295.5M	—	—	+34.36%	—	−13.24%	100.00%	(103.70%)

All 614 Biotechnology stocks →

Benitec Biopharma Limited (BNTC) key facts

Benitec Biopharma Limited (BNTC) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, BNTC traded at $8.11, a market capitalization of $295.1 million.
Return on equity was −33.2% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −66.02 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.